TCBalance Biopharmaceuticals

Executive Summary

TCBalance Biopharmaceuticals is a German pre-clinical company focused on addressing chronic diseases driven by pathogenic immune responses. These conditions, such as autoimmune disorders and transplant rejection, impose a significant healthcare burden with direct costs exceeding €120 billion annually in the EU alone. Current treatments rely on lifelong immunosuppression, which carries substantial side effects and high costs. TCBalance aims to develop a novel immunomodulatory therapy that restores immune balance by inducing tolerance to specific antigens without general immunosuppression. Founded in 1994, the company has been refining its platform for over three decades, leveraging deep expertise in cellular and molecular immunology. Although still in the pre-clinical stage, its approach holds potential to transform the standard of care for millions of patients.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical proof-of-concept studies60% success
• H1 2027IND filing for lead candidate40% success
• Q2 2027Partnership or licensing agreement for platform technology30% success